(Q35125390)

6 August 2017

1 reference

title

Treating dyslipidemic patients with lipid-modifying and combination therapies (English)

1 reference

6 August 2017

Treating Dyslipidemic Patients with Lipid‐Modifying and Combination Therapies (English)

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

1 January 2024

author name string

Michael Bottorff

2

1 reference

6 August 2017

Chad R. Worz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12741437

1 January 2024

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1592%2Fphco.23.5.625.32204

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

https://onlinelibrary.wiley.com/doi/full/10.1592/phco.23.5.625.32204

1 January 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

1 January 2024

1 reference

6 August 2017

volume

23

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

625-637

1 reference

Cholesterol and mortality. 30 years of follow-up from the Framingham study

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Management of primary mixed hyperlipidemia with lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Niacin dosing: relationship to benefits and adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Fulminant hepatic failure after ingestion of sustained-release nicotinic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Fibric acids: effects on lipids and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Gallbladder Disease as a Side Effect of Drugs Influencing Lipid Metabolism Experience in the Coronary Drug Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

FDA adverse event reports on statin-associated rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Statin-fibrate combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Case of the month: February 1999--54 year old man with severe muscle weakness

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.5.625.32204

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Cholesterol and mortality. 30 years of follow-up from the Framingham study

1 January 2024

3

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

The continuing epidemics of obesity and diabetes in the United States

1 January 2024

4

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

The spread of the obesity epidemic in the United States, 1991-1998

1 January 2024

5

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 January 2024

7

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial

1 January 2024

24

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease

1 January 2024

27

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative

1 January 2024

34

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia

1 January 2024

35

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia

1 January 2024

39

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

1 January 2024

40

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol

1 January 2024

45

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 January 2024

48

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid

1 January 2024

49

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Nicotinic acid-induced fulminant hepatic failure

1 January 2024

53

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

1 January 2024

55

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Understanding niacin formulations

1 January 2024

57

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial

1 January 2024

58

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group

1 January 2024

60

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Gemfibrozil interaction with warfarin sodium (coumadin)

1 January 2024

66

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism

1 January 2024

68

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 January 2024

69

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia

1 January 2024

78

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil.

1 January 2024

81

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia

1 January 2024

83

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Fluvastatin with and without niacin for hypercholesterolemia

1 January 2024

85

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

Lovastatin, nicotinic acid, and rhabdomyolysis

1 January 2024

88

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.5.625.32204

1 January 2024

Identifiers

1 reference

6 August 2017

1 reference